ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Cleavage and polyadenylation-specific factor 3 induces cell cycle arrest via PI3K/Akt/GSK-3β signaling pathways and predicts a negative prognosis in hepatocellular carcinoma

Li, Ning; Jiang, Shaotao; Fu, Rongdang; Lv, Jin; Yao, Jiyou; Mai, Jialuo; Hua, Xuefeng; Chen, Huan; Liu, Jie; Lu, Minqiang*佛山市第一人民医院; 中山大学; 1
Biomarkers in Medicine2021-4DOI: 10.2217/bmm-2021-0039
5被引6阅读
引用收藏
分享

摘要

Background: Recent studies have shown that cleavage and polyadenylation-specific factor 3 (CPSF3) is a promising antitumor therapeutic target, but its potential role in hepatocellular carcinoma (HCC) has not been reported. Materials & methods: We explored the expression pattern of CPSF3 in HCC through bioinformatics analysis, quantitative polymerase chain reaction (qPCR) and western blot. The potential role of CPSF3 as a biomarker for HCC was evaluated by Kaplan-Meier analysis. Next, changes in HCC cell lines in the CPSF3 knockdown model group and the control group were assessed by Cell Counting Kit-8, clonal formation, flow cytometry and EdU staining. Western blot detected changes in protein levels of the PI3K/Akt/GSK-3 beta axis of two HCC cell lines in the knockdown group and the control group. Results: The results showed that the transcription and protein levels of CPSF3 were significantly higher in HCC tissues than in adjacent normal tissues (p < 0.05). The HCC cohort with increased expression of CPSF3 is associated with advanced stage and differentiation and predicts poorer prognosis (p < 0.05). CPSF3 knockdown significantly inhibited proliferation and clone formation of HepG2 and SMMC-7721 cell lines. Flow cytometry analysis showed G1-S cell cycle arrest in the CPSF3 knockdown group, and the results of EdU staining were consistent with this. Compared with the control group, p-Akt and cyclin D1 were decreased, and GSK-3 beta was increased in the knockdown group. Conclusion: CPSF3 may be a potential diagnostic biomarker and candidate therapeutic target for HCC.

学科与关键词

关键词
biomarkercell cycleCPSF3hepatocellular carcinomaPI3KAktGSK-3&#946
相关
加载中…
  • Identification of PAFAH1B3 as Candidate Prognosis Marker and Potential Therapeutic Target for Hepatocellular Carcinoma
    Xu, Weikang; Lu, Xinyu; Liu, Jing; Chen, Qianhui; Huang, Xuan; Huang, Kuiyuan; Liu, Hongyan*; Zhu, Wei*; Zhang, Xiaoyong*Frontiers in Oncology, 2021, 11.被引 4
  • Upregulation of SKA3 enhances cell proliferation and correlates with poor prognosis in hepatocellular carcinoma
    Tang, Jianxin; Liu, Jing; Li, Jinjun; Liang, Ziming; Zeng, Kaining; Li, Haibo; Zhao, Zhenlin; Zhou, Li*; Jiang, Nan*Oncology Reports, 2021, 45(4): 48.被引 5
  • The miR-590-3p/CFHR3/STAT3 signaling pathway promotes cell proliferation and metastasis in hepatocellular carcinoma
    Wan, Zhongzhong; Li, Xingrun; Luo, Xinru; Wang, Bofan; Zhou, Xiang*; Chen, Ao*Aging-US, 2022, 14(14): 5783-5799.被引 7
查看全部 →

发表信息

论文状态
公开发表
期刊
Biomarkers in Medicine
发表日期
2021-04
卷期
第 15 卷, 第 5 期
页码
347-358
DOI
10.2217/bmm-2021-0039
语言
ENGLISH
期刊收录
NSL
期刊等级
4区
成果收录
SCIE

作者

  • L

    Li, Ning (第一作者)

    1 · 2

  • J

    Jiang, Shaotao

    1 · 2

查看全部 10 位作者收起作者
  • F

    Fu, Rongdang

    peoples hosp foshan 1 · sun yat sen univ

  • L

    Lv, Jin

    peoples hosp foshan 1 · sun yat sen univ

  • Y

    Yao, Jiyou

    1 · 2

  • M

    Mai, Jialuo

    1 · 2

  • H

    Hua, Xuefeng

    1 · 2

  • C

    Chen, Huan

    1 · 2

  • L

    Liu, Jie

    1 · 2

  • L

    Lu, Minqiang (通讯)

    1 · 2

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417